Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Clear Secure Inc (YOU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Clear Secure Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $223.91 (market cap $29.60B), while Clear Secure Inc trades at $46.82 (market cap $4.98B). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 5.9× Clear Secure Inc's market cap, and Clear Secure Inc pays a 1.19% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | YOU | |
|---|---|---|
Market Cap | $29.60B | $4.98B |
Sector | Health | Technology |
52-Week High | $491.22 | $62.36 |
52-Week Low | $205.48 | $29.61 |
Enterprise Value | $27.56B | $4.13B |
Dividend Yield | — | 1.19% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $222.54, up 2.56% today, amid a bearish technical signal with support at $218 and resistance at $223. The company reported strong revenue growth to $3.71B in 2025 and turned profitable with net income of $313.75M, though recent Q2 2026 earnings missed estimates. Analyst consensus remains bullish with a $370.07 price target, but multiple law firms are investigating potential securities fraud, creating near-term uncertainty.
The outlook is mixed: robust fundamentals and analyst support suggest long-term upside, but legal risks and recent earnings volatility pose significant headwinds. Investors face tension between strong profitability metrics and heightened sentiment risks from ongoing investigations.
CLEAR Secure (YOU) trades at $46.98, down 8.26% in 24 hours, reflecting recent bearish pressure but holding above key support at $45. The stock shows strong fundamentals with Q2 2026 earnings beating estimates at $0.49 per share, revenue growth to $1.0 billion in 2026, and robust profitability margins. Technical indicators are mixed, with moving averages bearish but oscillators like RSI suggesting potential oversold conditions. Recent news highlights expansion in identity verification services and corporate memberships.
Outlook is cautiously optimistic due to earnings beats and growth initiatives, but risks include high valuation multiples and market volatility. Analysts are divided with a near-even buy/hold split, indicating balanced sentiment. Investors should weigh strong operational cash flow against competitive pressures in the identity security sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Clear Secure Inc
Clear Secure operates a secure identity platform that uses biometrics—specifically eyes, face, and fingerprints—to automate and expedite identity verification. While its most visible application is the CLEAR Plus airport subscription service, the company functions as a broad-based identity layer for travel, healthcare, and digital services, aiming to replace physical IDs with a secure, biometric link.
Read more on YOU →
